AstraZeneca Executive and Leadership Team

Aradhana Sarin, the Executive Director & Chief Financial Officer at AstraZeneca, directs the company's global financial strategy and operations. This leadership role involves overseeing all aspects of financial planning, reporting, and capital allocation to support AstraZeneca's core mission in oncology and bio-pharmaceuticals. Sarin's responsibilities extend to managing investor relations and ensuring fiscal discipline across all business units. The Chief Financial Officer drives initiatives to optimize financial performance and resource deployment, directly contributing to the company's ability to fund critical research and development projects. By maintaining robust financial controls and forecasting, Aradhana Sarin ensures the long-term economic health and strategic growth of AstraZeneca's operations worldwide.

Joey Zhu, the Chief Financial Officer, PA To The at AstraZeneca, provides critical financial support and strategic advisory to the Chief Financial Officer. This role involves assisting in the management of financial planning, analysis, and reporting to ensure fiscal integrity across the organization. Zhu's responsibilities include supporting key financial initiatives and contributing to the strategic decision-making processes that drive AstraZeneca's growth in oncology and bio-pharmaceuticals. The Chief Financial Officer's support function ensures operational efficiency within the finance department. By facilitating financial operations and contributing to strategic financial planning, Joey Zhu plays an integral part in maintaining AstraZeneca's financial health and supporting its mission to develop life-changing medicines.

Richard Hasselbusch, the Vice President and Chief Financial Officer, Global Operations and Information Technology at AstraZeneca, leads financial strategy for global operations and IT. This executive role involves overseeing financial planning, budgeting, and performance management for critical operational and technological infrastructure supporting AstraZeneca's global reach. Hasselbusch's responsibilities include ensuring fiscal efficiency and driving financial optimization across complex supply chains and IT systems. The Chief Financial Officer's focus on these areas is vital for supporting the company's bio-pharmaceutical and oncology development efforts. By managing financial resources effectively and providing strategic financial insights, Richard Hasselbusch ensures robust operational and technological support for AstraZeneca's mission.

Santiago Rivera, the Chief Financial Officer & Chief Financial Officer, Andean Cluster at AstraZeneca, directs financial operations and strategy for the Andean region. This leadership role is crucial for managing financial performance, ensuring compliance, and driving fiscal growth within this key geographic market. Rivera's responsibilities include overseeing financial planning, analysis, and reporting to support AstraZeneca's commercial objectives in oncology and bio-pharmaceuticals. The Chief Financial Officer's strategic oversight ensures optimal resource allocation and financial discipline across the cluster. By providing critical financial leadership and insights, Santiago Rivera significantly contributes to AstraZeneca's regional success and its overarching mission to deliver life-changing medicines.

Bhavana Agrawal, the Chief Financial Officer (India) at AstraZeneca, leads financial strategy and operations for the Indian market. This executive position is vital for managing financial performance, driving fiscal growth, and ensuring compliance within one of AstraZeneca's key global territories. Agrawal's responsibilities encompass financial planning, analysis, and reporting, directly supporting the commercialization of oncology and bio-pharmaceutical products in India. The Chief Financial Officer's strategic financial guidance optimizes resource allocation and enhances operational efficiency. By providing strong financial leadership and market-specific insights, Bhavana Agrawal plays a critical role in advancing AstraZeneca's mission and expanding access to its life-changing therapies within the region.

David Auerbach, the Strategy, Transformation Operations Leader & Global Chief Operating Officer, Head of Tmo, Oncology Research & Development at AstraZeneca, spearheads operational excellence within the oncology research and development division. This critical leadership position involves driving transformation initiatives and optimizing operational processes to accelerate the discovery and delivery of new cancer therapies. Auerbach oversees the strategic implementation of operational frameworks, ensuring efficient resource allocation and project management across global R&D efforts. The Chief Operating Officer's focus on transformation operations directly supports AstraZeneca's commitment to advancing oncology treatments. By enhancing operational capabilities and fostering innovation, David Auerbach plays a pivotal role in advancing the company's pipeline and market impact.

Jennifer Givens, the Management Director, Operations & Chief Operating Officer, Oncology Research & Development at AstraZeneca, directs the operational execution and strategic management of the oncology R&D division. This leadership position is central to advancing AstraZeneca's pipeline of cancer treatments by ensuring efficient and effective research and development processes. Givens oversees critical operational functions, driving innovation and optimizing resource allocation to accelerate drug discovery and clinical trials. The Chief Operating Officer's mandate includes enhancing operational capabilities and fostering a culture of scientific excellence. By managing complex projects and ensuring seamless integration of operational strategies, Jennifer Givens significantly contributes to AstraZeneca's mission of delivering life-changing therapies.

Suzanne Pearen, the Administrative Coordinator & Chief Operating Officer, Oncology Research & Development at AstraZeneca, enhances operational efficiency within the oncology R&D division. This dual-focused role supports strategic operational execution and ensures seamless administrative coordination for critical research initiatives. Pearen's responsibilities include optimizing workflows and managing key projects to accelerate the development of novel cancer therapies. The Chief Operating Officer's focus on operational excellence directly supports AstraZeneca's commitment to advancing oncology treatments. By streamlining processes and facilitating effective collaboration, Suzanne Pearen contributes significantly to the timely delivery of life-changing medicines from discovery through to clinical application.

Daniel Evangelista, the Market Access & Strategic Affairs Chief of Staff at AstraZeneca, supports the strategic direction and operational execution of market access initiatives. This role focuses on ensuring that AstraZeneca's innovative medicines reach patients effectively by navigating complex healthcare systems and regulatory landscapes. Evangelista's work involves coordinating cross-functional teams to develop and implement strategies that enhance patient access to therapies in oncology and bio-pharmaceuticals. The Chief of Staff drives operational efficiency within the strategic affairs division, facilitating communication and alignment across global and regional teams. By managing key projects and driving strategic planning processes, Daniel Evangelista contributes significantly to AstraZeneca's mission of delivering life-changing treatments.

Katharine Oteiza, the Director, BPO - Biometrics Chief of Staff at AstraZeneca, manages operational efficiency and strategic alignment within the biometrics function. This role is crucial for ensuring the integrity and timely delivery of clinical trial data, which underpins the development of AstraZeneca's innovative medicines. Oteiza's responsibilities include overseeing business process outsourcing relationships and driving process improvements to enhance data quality and analytical capabilities. The Chief of Staff role supports the strategic objectives of the biometrics department, facilitating seamless collaboration between internal teams and external partners. By optimizing operational workflows and ensuring adherence to regulatory standards, Katharine Oteiza contributes to the robust development of therapies in oncology and bio-pharmaceuticals.